Navigation Links
Oracle Buys Relsys
Date:3/23/2009

Adds Advanced Drug Safety and Risk Management Applications to Extend Oracle's Leadership in Health Sciences

REDWOOD SHORES, Calif., March 23 /PRNewswire-FirstCall/ --

News Facts

  • Oracle today announced that it has agreed to acquire Relsys International, Inc. ("Relsys"), a leading provider of drug safety and risk management solutions with advanced analytics for the health sciences industry.
  • Relsys' best-in-class solutions support adverse event reporting, risk management, and data analysis for pharmaceutical, biotechnology, contract research organizations and medical device companies worldwide.
  • The combination of Oracle and Relsys is expected to deliver the only suite of software applications that supports end-to-end drug safety processes across clinical development, post-market surveillance and patient care, and is expected to extend Oracle's leadership in providing drug safety applications to the health sciences industry.
  • The addition of Relsys will bring significant domain knowledge and experience as part of Oracle's Health Sciences Global Business Unit, and is consistent with Oracle's strategy to provide mission-critical applications for key industries.
  • The transaction is subject to customary closing conditions and is expected to close in the first half of calendar year 2009.
  • Until the deal closes, each company will continue to operate independently.
  • Financial details of the transaction were not disclosed.

Supporting Quotes

  • "The health sciences industry is increasing investments in software that provide greater transparency into drug safety and help improve the overall safety of therapies," said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. "With the addition of Relsys, Oracle is uniquely positioned to help our customers improve drug safety by delivering a comprehensive software solution that enables our vision of integrated safety and risk management supported by advanced analytics."
  • "Identifying safety issues earlier in the development process can significantly reduce the costs and risks associated with bringing drugs and devices to market," said Dave Bajaj, President & CEO, Relsys. "Industry leaders trust Relsys' solutions to help them capture these benefits. We look forward to joining Oracle and helping provide the health sciences industry with the most complete, open and integrated suite of enterprise software."

Supporting Resources

About Oracle

Oracle (Nasdaq: ORCL) is the world's largest business software company. For more information about Oracle, please visit our Web site at http://www.oracle.com/.

Trademarks

Oracle is a registered trademark of Oracle Corporation and/or its affiliates. Other names may be trademarks of their respective owners.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020718/ORCLLOGO)


'/>"/>
SOURCE Oracle
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. TCS, Oracle and DrugLogic Prescribe Safety in a Capsule(TM)
2. Oracle Helps Mayo Clinic Improve Information Management
3. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
4. Oracle Introduces Remote Data Capture Onsite 4.5.3 With Extensive New Functionality for Investigative Site Personnel
5. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
6. Oracle Healthcare Acquisition Corp. Changes Record Date and Date of Special Meeting to Consider and Vote on Dissolution and Plan of Liquidation
7. Oracle Healthcare Acquisition Corp. Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation
8. MedTrust Online Collaborates With Oracle and Dell to Provide Oncologists With the Next Generation Tool for Personalized Care Delivery
9. Vgo Software First to Convert Oracle Forms to Oracle ADF v11
10. Sermes CRO Deploys Oracle(R) Clinical Applications to Support Growth
11. Bruce Palsulich Joins Relsys International as Chief Innovation & Strategy Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the Blüm Study, ... children aged 3-8 with Autism, is now enrolling at three new sites. These new ... United States. , “There are currently no approved drugs that address the core ...
(Date:2/23/2017)... ... February 23, 2017 , ... Carlos Gutierrez has lived ... continued to spiritually evolve, which is the purpose of everyone in this universe. As ... ” (published by Balboa Press) attempts to guide readers to expand one’s spiritual life. ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Gevir, a ... deer antler velvet, announced its products are coming soon to Amazon.com, the world’s largest ... Shelley Thomson as a means to develop an effective natural treatment for Shelley’s Multiple ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... secure messaging services to the largest network of hospitals, health information exchanges, ... National Coordinator for Health Information Technology (ONC-HIT) 2015 Edition Health IT Module Certification ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... approach, leads to fewer trips the emergency room, fewer hospital admissions, and better ... Journal of Managed Care® (AJMC®) finds. The study can be found here ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... York , February 23, 2017 ... Holter Monitor Market are GE Healthcare, Koninklijke Philips N.V., ... about 48% in the global market in 2015. Strong ... two key factors assessed to be aiding these players ... Research states that the players in the global market ...
(Date:2/23/2017)... February 23, 2017 Tillotts Pharma ... Berlin office was opened in ... . The portfolio includes Entocort ® for the ... treatment of ulcerative colitis, and VistaPrep ® for ... Swiss specialty pharmaceutical company focused on the treatment of ...
(Date:2/23/2017)... and VANCOUVER, British Columbia , Feb. ... OGXI ) today announced its year end 2016 financial ... In January 2017, OncoGenex, and Achieve Life Science, Inc., a ... entered into a definitive merger agreement under which OncoGenex ... of the proposed merger, Achieve,s stockholders are expected to ...
Breaking Medicine Technology: